KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other financing activities: 2018-2025

Historic Other financing activities for Rigel Pharmaceuticals (RIGL) over the last 7 years, with Sep 2025 value amounting to $4.3 million.

  • Rigel Pharmaceuticals' Other financing activities rose 2603.16% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 573.91%. This contributed to the annual value of $2.0 million for FY2024, which is 87.23% up from last year.
  • Rigel Pharmaceuticals' Other financing activities amounted to $4.3 million in Q3 2025, which was up 921.77% from $418,000 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Other financing activities registered a high of $4.3 million during Q3 2025, and its lowest value of $1,000 during Q1 2023.
  • Over the past 3 years, Rigel Pharmaceuticals' median Other financing activities value was $418,000 (recorded in 2025), while the average stood at $744,182.
  • In the last 5 years, Rigel Pharmaceuticals' Other financing activities slumped by 99.89% in 2023 and then soared by 8,800.00% in 2024.
  • Rigel Pharmaceuticals' Other financing activities (Quarterly) stood at $1.1 million in 2021, then tumbled by 54.59% to $599,000 in 2022, then declined by 7.51% to $486,000 in 2023, then skyrocketed by 201.44% to $1.5 million in 2024, then skyrocketed by 2,603.16% to $4.3 million in 2025.
  • Its Other financing activities stands at $4.3 million for Q3 2025, versus $418,000 for Q2 2025 and $484,000 for Q1 2025.